Latest News & Features
Generics
AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents. 8 February 2022
Europe
The European Commission will unveil plans to make supplementary protection certificates more accessible and efficient for pharmaceutical companies to register and enforce by the end of March. 8 February 2022
Big Pharma
Pharmaceutical industry consortium PhRMA has asked the Office of the US Trade Representative to put the European Union, the World Trade Organization and the UK on a watch list of trading partners that could “weaken” IP rights. 7 February 2022
Big Pharma
Pfizer has sued two of its former executive staffers, alleging that they stole trade secrets related to diabetes medication before leaving the company. 3 February 2022
Big Pharma
Gilead Sciences has agreed to pay $1.25 billion upfront with additional royalties to GlaxoSmithKline subsidiary ViiV Healthcare to settle claims that it infringed HIV drug patents. 3 February 2022
Americas
Novartis escaped an antitrust countersuit brought by Regeneron earlier this week, with a New York court dismissing the suit which had been filed in response to Novartis’ patent complaint. 3 February 2022
article
Tune in to hear from a panel of leading patent attorneys from Europe and the US as they discuss some key strategies for protecting your IP and how to minimize your risk when filing patents internationally. What are the vital considerations for patent prosecutions at both the USPTO and EPO? Hear from our panel how to overcome the latest challenges to patent procurement in both jurisdictions. 3 February 2022
Big Pharma
UK politicians are proposing that the country waive UK registered IP related to vaccines and treatments in the event of a pandemic. 1 February 2022
Americas
Bristol-Myers Squibb subsidiary, Celgene has settled its lawsuit against India-based drug maker Dr Reddy's over a generic version of the blockbuster cancer treatment, Pomalyst. 1 February 2022
article
A landmark proposal to suspend provisions of TRIPS for COVID-19 vaccines and treatments was first raised in October 2020. But, nearly a year and a half later, in January 2022, it seems there is no end in sight, with members of the World Trade Organization failing to reach consensus. 1 February 2022